Announcement • Apr 29
Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024 Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day. Announcement • Apr 10
Vitrolife AB (publ) Announces CFO Changes Vitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office. Announcement • Mar 31
Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp Innovation Vitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson. Announcement • Feb 21
The Vitrolife Group Appoints Ermanno Sironi as Chief Operating Officer The Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team. Announcement • Jan 31
Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025 Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Sweden Announcement • Jan 30
Vitrolife AB (Publ) Proposes Dividend The Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share. Announcement • Dec 03
Vitrolife AB (Publ) Announces Chief Financial Officer Changes Vitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated. Announcement • Nov 16
Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025 Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025 Announcement • Oct 27
Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026 Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026 Announcement • Oct 04
Vitrolife AB (Publ) Announces Election Committee Appointments Vitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024. Announcement • May 23
Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V. Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million. Announcement • May 03
Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million. Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash. Announcement • Apr 27
Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023 Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day. Announcement • Jan 24
Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023 Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021. Announcement • Oct 06
Vitrolife AB (publ) Announces Election Committee Appointments Vitrolife AB (publ) announced the following people have been appointed as members of the election committee for the Annual General Meeting in 2024: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Caroline Sjösten, appointed by Swedbank Robur Fonder AB; and Jón Sigurdsson, Chairman of the Board. Announcement • Aug 24
Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President Vitrolife AB (publ) announced that Maria Forss, has resigned from her position as SVP Consumables business area in the company as she will assume the role of CEO BICO Group AB. Maria has been employed within the company since 2012 and has been leading the Consumables business area since 2017. Announcement • Aug 01
Vitrolife AB Announces Board Changes Vitrolife AB (publ) announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from August 1, 2023, when Bronwyn Brophy assumes the position as CEO. The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today. After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee. Announcement • Feb 01
Vitrolife AB (publ) Announces Executive Changes Vitrolife AB (publ) appointed Bronwyn Brophy as new CEO. Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors of the company find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023. 
